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Supplementary Figures and Tables 
Supplementary Figure 1. IRAK4i suppresses p-IRAK4 and p-p65 staining in colon tissue 
Representative IHC pictures of the indicated markers from colonic tissues from DSS-treated APCMin/+ 
mice followed by vehicle or IRAK4i treatment for 4 weeks. Suppression of p-IRAK4 and p-p65 
supports on-target effect of IRAK4i. Colonic epithelium near a lymphoid aggregate was selected for 
presentation. 
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Supplementary Figure 2. IRAK4 expression is upregulated in CRC samples 
(A) Western blots showing lack of definite short (~32kDa) IRAK4 band in tested CRC lines using a
commercial antibody raised against the C-terminus of IRAK4 (Abcam #5985).
(B) Comparison of p-IRAK4 IHC intensities by H scores in CRC samples of different clinical stages from
a pool of 5 commercial TMAs (Tukey’s multiple comparison test, ns: not significant).
(C) Comparison of IRAK4 mRNA expression between normal and colon cancer tissues from three
different datasets in Oncomine.
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Supplementary Figure 3. Essential role of IRAK4 in NF-B activity and tumorigenesis 
(A) NF-B luciferase reporter assay of the indicated KM12 cells transfected with empty vector, wild-type 
(WT) or constitutively activated (S177E/S181E) IKK. Data presented as mean ± SEM from one of 
two experiments done in triplicates (ANOVA, **p<0.01, ***p<0.001).
(B) Western bots showing restoration of IRAK4 expression in re-cultured and puromycin-selected MC38 
tumor lines harvested from terminal mice in experiments Fig. 4F and 4G.
(C) Western blots showing suppressive effect of IRAK4i PF06650833 on p-IRAK4 and p-IRAK1 in 
normal colon cell line FHC.
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Supplementary Figure 4. IRAK4 inhibition suppresses NF-B and potentiates chemotherapy 
(A) (B) NF-B luciferase reporter assay of three different CRC cell lines treated with oxaliplatin or 5-FU 
(0, 10 or 20M) and AS2444697 (AS) or PF06650833 (PF) at 0, 4, 8 M overnight. Data represent 
one of three sets of experiment each done in triplicates and presented as mean ± SEM (*p<0.05, 
**p<0.01, ***p<0.001).
Western blots showing increased PARP cleavage in two different CRC cell lines treated for 24 hours 
with IRAK4 inhibitors (both at 4M) and 5-FU or oxaliplatin (both at 10M).
Dose-response curves based on Alamar Blue viability assay on two CRC cell lines stably expressing 
scramble or IRAK4 shRNAs incubated in the indicated chemotherapeutic agent at 8 different 
concentrations over 5 days. Data represent one of three sets of experiment each done in triplicates 




Supplementary Figure 5. Chemotherapy induces TLR9 expression and cleavage 
Western blots showing enhanced protein level of full length and cleaved form of TLR9-YFP in 293T cells 
transfected with TLR9-YFP in 293T cells. To ensure equal basal expression, 293T cells were transfected 
with TLR9-YFP, and 24 hours later split into halves for treatment with DMSO or 5-FU + oxaliplatin (10M 
each) overnight before being harvested for lysis. Experiment was conducted three times with similar 
results.    
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Supplementary Figure 6. IRAK4 inhibitors potentiate chemotherapy and are well-tolerated in 
mice 
(A) Representative H&E and p-IRAK4, p-p50 IHC images from DLD-1 and KM12 tumors harvested 
from experiment in Fig. 7C and 7G, respectively. (n: necrotic areas)
(B), (C) Serial measurements of body weight of mice bearing DLD-1 or KM12 tumors treated as 
indicated following treatment start. Data presented as means ± SEM.
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Supplementary Figure 7. Chemotherapy induces TLR9 expression in pancreatic cancer cells 
qPCR showing fold change of TLR9 mRNA levels in MIA Paca-2 cells treated overnight with various 
chemotherapeutic agents (all in 10M). Data represents one of two sets of experiments done in 




Supplementary Table 1. Clinicopathologic characteristics of all Stage IV colon cancer patients 











p-IRAK H-score  
low-medium (N=136) 




    Male 









    Median 








Presentation of liver metastasis 
    Synchronous 











Number of liver metastasis 
    Median 
               Mean 
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Extent of liver surgery 





























Median overall survival 
(resection to death, years) 
3.81 













Name Host Clone# Company Dilution 
p-IRAK4(T345/S346), WB Rabbit D6D7 Cell Signaling 1:1000 
Total IRAK4 Rabbit 4363 Cell Signaling 1:1000 
Total IRAK4 (C-terminus) Rabbit ab5985 Abcam 1:500 
p-IRAK1(T209) Rabbit N/A Cell Signaling 1:1000 
Total IRAK1 Rabbit D51G7 Cell Signaling 1:1000 
p-IKKα/β(S176/180) Rabbit N/A Cell Signaling 1:1000 
Total IKKβ Rabbit 2C8 Cell Signaling 1:1000 
p-NF-κB/p65(S536) Rabbit ab86299 Abcam 1:250 
Total NF-κB/p65 Rabbit D14E12 Cell Signaling 1:1000 
p-NF-κB/p50(S337) Mouse A-8 Santa Cruz 1:200 
Total NF-κB p105/p50 Rabbit N/A Cell Signaling 1:1000 
GAPDH Mouse 0411 Santa Cruz 1:1000 
α-tubulin Mouse B-7 Santa Cruz 1:500 
Histone H3 Rabbit D1H2 Cell Signaling 1:1000 
PARP Rabbit N/A Cell Signaling 1:1000 
Ki-67 Mouse 8D5 Cell Signaling 1:50 
Cleaved Caspase-3 Rabbit 5A1E Cell Signaling 1:200 
Pan-cytokeratin Mouse C11 Cell Signaling 1:400 
β-tubulin Rabbit 9F3 Cell Signaling 1:2000 
p-IRAK4 (T345), IHC and IF Mouse A8A8 ABNOVA 1:250~500 
TLR9 Rabbit D9M9H 
D2C9 
Cell Signaling 1:1000 
